Gynecologic Cancers

P2, N=130, Recruiting, Shanghai Henlius Biotech | N=60 --> 130

P=N/A, N=22, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

Clinical utility of MCD testing for symptomatic patients in the United Kingdom varies substantially across referral pathways but is favorable for gynecologic and GI cancers. Future pathway-specific optimization of MCD tests must consider clinical utility explicitly and does not require retraining the underlying machine learning classifiers.

P=N/A, N=510, Recruiting, University Health Network, Toronto | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

Trastuzumab-based therapy has shown survival benefit in HER2-positive SEC, leading to its inclusion in current treatment guidelines...The prognostic value remains debated, though recent trials of antibody-drug conjugates (e.g., T-DXd) show promise...Diagnostic challenges include variable scoring systems, intratumoral heterogeneity, and HER2-low classification. Standardization of testing criteria and further clinical validation of HER2-targeted strategies across gynecologic tumors are essential to guide personalized therapy and improve outcomes.

XLT has anti-tumor effects by inducing apoptosis and inhibiting migration of tumor cells. The formula showed notable efficacy, comparable to conventional treatments (chemotherapy) but with greater safety, suggesting that it may be suitable for clinical translation in the treatment of cervical cancer.

ECs with MECOM amplification are associated with poor clinical outcomes, even in the absence of CCNE1 or ERBB2 amplification. The current literature is limited, and further studies are warranted to determine the role of MECOM amplification in ECs.

P=N/A, N=90, Recruiting, Vejle Hospital | Not yet recruiting --> Recruiting

In vitro, FAM172A promoted malignant behavior and conferred resistance to cisplatin...These findings highlight FAM172A as a critical promoter of EOC progression, associated with aggressive tumor characteristics and treatment failure. By activating the PI3K-Akt pathway, FAM172A represents a promising therapeutic target for EOC, potentially offering new strategies to improve patient outcomes, particularly in overcoming chemoresistance.

Elevated ZNF280A or ACRV1 expression activated PI3K/AKT signaling and increased glycolytic enzyme expression (PKM2, LDHA), glucose uptake, lactate production, ATP generation, and extracellular acidification rate, whereas pharmacological inhibition of AKT or glycolysis abrogated these effects. Collectively, our findings establish ZNF280A as a key regulator of metabolic reprogramming in OC through the CUX2-ACRV1-PI3K/AKT axis, highlighting this pathway as a potential therapeutic target in ovarian cancer.

Epithelial ovarian carcinoma, the deadliest gynecological malignancy, frequently develops treatment resistance through polyploid giant cancer cells (PGCCs) that typically emerge after carboplatin-paclitaxel chemotherapy. Our findings establish that the cytoplasmic SIRT1/β-catenin axis contributes to PGCC stemness, elucidating a novel mechanism underlying chemoresistance. Therefore, targeting cytoplasmic SIRT1 represents a promising therapeutic strategy to overcome PGCC-mediated resistance in this lethal carcinoma.

The released "spears" containing N-cadherin-targeting moiety and fluorophore can specifically recognize the ovarian tumor cells, thereby facilitating the visualization of primary or metastatic tumor regions. Overall, this study highlights the potential of RBC-hitchhiking fluorescent probes in advancing the intraoperative diagnosis of human ovarian tumor tissues during the fluorescence-guided surgery process in clinics.